Related Experiment Video
Updated: Jul 14, 2026
A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English
Published on: April 3, 2026
Structure-based discovery of a new class of Bcl-xL antagonists
Michele F Rega1, Marilisa Leone, Dawoon Jung
1Burnham Institute for Medical Research, Cancer Center and Infectious and Inflammatory Disease Center, La Jolla, CA 92037, USA.
Abstract:
Apoptosis, or programmed cell death, plays a key role in normal tissue homeostasis ensuring a proper balance between cell production and cell loss. Anti-apoptotic Bcl-2-family proteins are central regulators of the apoptotic pathway and due to their ability to confer tumor resistance to chemotherapy or radiation, have been recently validated as targets for cancer drug discovery. Since the crucial interaction between pro- and anti-apoptotic members occurs via a conserved region located on the surface of the protein, a viable way to inhibit the anti-death activity of Bcl-2 proteins is to design small molecule inhibitors that occupy this cavity. Here, we describe a structure-based approach that led to the identification of four small molecule inhibitors directed at the hydrophobic groove on the surface of the Bcl-2 family protein Bcl-xL. The compounds were characterized in a number of assays including in vitro binding using 15N-labeled protein, a displacement DELFIA assay, and a cell-based viability assay with human cancer cells.
Insights
Researchers identified four small molecules targeting Bcl-xL, a protein involved in programmed cell death and cancer resistance. These inhibitors offer a new strategy for cancer drug discovery by blocking anti-apoptotic protein activity.
Area of Science:
- Molecular Biology
- Biochemistry
- Cancer Research
Background:
- Apoptosis (programmed cell death) is crucial for tissue homeostasis.
- Anti-apoptotic Bcl-2 proteins regulate cell death and confer resistance to cancer therapies.
- Targeting Bcl-2 proteins is a promising strategy for cancer drug discovery.
Purpose of the Study:
- To identify small molecule inhibitors of the anti-apoptotic Bcl-2 protein, Bcl-xL.
- To explore a structure-based approach for designing inhibitors targeting the Bcl-xL hydrophobic groove.
Main Methods:
- Structure-based drug design targeting Bcl-xL.
- In vitro binding assays using 15N-labeled Bcl-xL.
- Displacement DELFIA assay.
- Cell-based viability assays with human cancer cells.
Main Results:
- Identification of four small molecule inhibitors targeting the Bcl-xL hydrophobic groove.
- Characterization of inhibitor binding and functional activity.
- Demonstration of inhibitor efficacy in cell-based cancer models.
Conclusions:
- Small molecule inhibitors targeting the Bcl-xL hydrophobic groove can be successfully identified using a structure-based approach.
- These inhibitors represent potential therapeutic agents for cancers resistant to conventional treatments.
- Further development of these compounds may lead to novel cancer therapies.
More Related Videos
06:56A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4
Published on: March 10, 2018
10:44Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
Related Concept Videos
01:25Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
01:26Drug Discovery: Overview